LEE, Kwang-Hoon,LEE, June Hyung,LEE, Na Rae,JEONG, Eunjeong,PARK, Young Bong,CHANG, Nakho,LEE, Eun-Jung,KIM, Ki Hong,CHOI, Sunghyun,CHOI, Byung Hyun,PARK, Ju Young,SONG, Moo Young,LEE, Jong-Seo,KIM, K
申请号：
AU2019229076
公开号：
AU2019229076A1
申请日:
2019.02.28
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.
